Manusiran

Manusiran (SLN124), a GalNAc conjugated 19-mer siRNA targeting TMPRSS6 (transmembrane protease serine 6), reduces plasma iron and increases hepcidin levels of healthy volunteers[1][2].

Product Specifications

CAS Number

[2646704-10-9]

Product Name Alternative

Divesiran

UNSPSC

12352208

Target

Ser/Thr Protease; Small Interfering RNA (siRNA) ; TMPRSS6

Type

Oligonucleotides

Related Pathways

Epigenetics; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/manusiran.html

Solubility

10 mM in DMSO

Smiles

[Manusiran]

Molecular Formula

C434H570F19N145O270P40S10

Molecular Weight

14058.53

References & Citations

[1]WHO Drug Information. International Nonproprietary Names for Pharmaceutical|[2]Vadolas J, Ng GZ, Kysenius K, et al. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia. Br J Haematol. 2021;194 (1) :200-210.|[3]Altamura S, Schaeper U, Dames S, et al. SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019;3 (6) :e301.